CN107349332A - 一种鹿胶口服液及其制备方法 - Google Patents
一种鹿胶口服液及其制备方法 Download PDFInfo
- Publication number
- CN107349332A CN107349332A CN201710591759.5A CN201710591759A CN107349332A CN 107349332 A CN107349332 A CN 107349332A CN 201710591759 A CN201710591759 A CN 201710591759A CN 107349332 A CN107349332 A CN 107349332A
- Authority
- CN
- China
- Prior art keywords
- deer horn
- horn glue
- oral liquid
- parts
- hot water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003292 glue Substances 0.000 title claims abstract description 71
- 241000282994 Cervidae Species 0.000 title claims abstract description 69
- 239000007788 liquid Substances 0.000 title claims abstract description 56
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 239000003245 coal Substances 0.000 claims abstract description 30
- 239000000779 smoke Substances 0.000 claims abstract description 30
- 239000000463 material Substances 0.000 claims abstract description 23
- 241000208340 Araliaceae Species 0.000 claims abstract description 21
- 235000008434 ginseng Nutrition 0.000 claims abstract description 21
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 20
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 50
- 239000000706 filtrate Substances 0.000 claims description 28
- 239000006228 supernatant Substances 0.000 claims description 19
- 238000005119 centrifugation Methods 0.000 claims description 17
- 239000000284 extract Substances 0.000 claims description 17
- 238000001914 filtration Methods 0.000 claims description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 12
- 235000013905 glycine and its sodium salt Nutrition 0.000 claims description 12
- 238000001556 precipitation Methods 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 235000021552 granulated sugar Nutrition 0.000 claims description 10
- 238000003809 water extraction Methods 0.000 claims description 10
- 241001468872 Fumagospora capnodioides Species 0.000 claims description 8
- 238000002386 leaching Methods 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 8
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 235000010241 potassium sorbate Nutrition 0.000 claims description 7
- 239000004302 potassium sorbate Substances 0.000 claims description 7
- 229940069338 potassium sorbate Drugs 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 6
- 235000019441 ethanol Nutrition 0.000 claims description 6
- 125000005909 ethyl alcohol group Chemical group 0.000 claims description 6
- 238000007654 immersion Methods 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 238000005238 degreasing Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 3
- 238000012163 sequencing technique Methods 0.000 claims description 3
- 239000000084 colloidal system Substances 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 11
- 230000002929 anti-fatigue Effects 0.000 abstract description 6
- 230000000259 anti-tumor effect Effects 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 5
- 230000036541 health Effects 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 4
- 231100000419 toxicity Toxicity 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 6
- 230000009182 swimming Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 241000283007 Cervus nippon Species 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 238000009777 vacuum freeze-drying Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000037831 Polygonatum sibiricum Species 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 235000010199 sorbic acid Nutrition 0.000 description 3
- 229940075582 sorbic acid Drugs 0.000 description 3
- 239000004334 sorbic acid Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000012048 forced swim test Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 241000282985 Cervus Species 0.000 description 1
- 241000283026 Cervus elaphus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- 241000876851 Scorias spongiosa Species 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 210000000003 hoof Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000004900 laundering Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
- A23L13/20—Meat products; Meat meal; Preparation or treatment thereof from offal, e.g. rinds, skins, marrow, tripes, feet, ears or snouts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Abstract
本发明涉及中药保健品领域,具体而言,涉及一种鹿胶口服液及其制备方法。按重量份计,所述鹿胶口服液主要由以下原料组份制成:鹿胶30~90份、人参30~90份、海绵胶煤炱菌多糖10~30份以及黄精90~150份。该鹿胶口服液药效好,纯中药配方,无明显的毒副反应;以口服液的形式用药,服用方便,效果好;能有效提升免疫力,抗疲劳和抗肿瘤作用显著。
Description
技术领域
本发明涉及中药保健品领域,具体而言,涉及一种鹿胶口服液及其制备方法。
背景技术
随着我国经济的高速发展,人民生活水平的提高,人们对食品提出了越来越高的要求。鹿全身都是宝,不仅鹿茸具有良好的保健作用和药用功效,其他如鹿鞭、鹿蹄筋、鹿心血、鹿胎膏等鹿产品都具有很好的保健和药用价值。而鹿皮保健品的开发和利用尚处在探索阶段。对鹿皮性质功能的研究已具有悠久的历史,明代李时珍所撰《本草纲目》中对鹿皮药性的描述为“性温,味咸;具解毒、补气、涩精,补血止血、补肾壮阳等功效;主治漏疮,白带,崩漏,滑精,治一切疮”。用梅花鹿(Cervus nippon Temminck)或马鹿(Cervus elaphusLinnaeus)的皮熬制可得鹿皮胶。鹿皮胶一般呈棕红色,质地硬而脆,断面光亮,对光照视呈半透明,有鹿皮胶的特有香气。
近年来,随着药学科技的进步和人民群众对药品质量的高要求,迫切需要将原固体胶剂型研制改为剂量准确,便于服用的口服液剂型。
有鉴于此,特提出本发明。
发明内容
本发明的目的在于提供一种鹿胶口服液,以解决上述问题。
本发明涉及一种鹿胶口服液,按重量份计,主要由以下原料组份制成:
鹿胶30~90份、人参30~90份、海绵胶煤炱菌多糖10~30份以及黄精90~150份。
本发明将既定重量份数的鹿胶、人参、海绵胶煤炱菌多糖与黄精进行配伍,制得的鹿胶口服液有效成分含量高,服用量小,可取得增强机体免疫力、抗疲劳、抗肿瘤的多重效果。
本发明还涉及如上所述鹿胶口服液的制备方法,包括:
1).将人参、黄精用热水浸提后离心后收集上清,浓缩后得到药材浸提液;
2).将鹿胶、海绵胶煤炱菌多糖、白砂糖加入热水中融化并充分混匀制得胶糖液;
3).将所述药材浸提液和所述胶糖液混合,离心后收集上清,浓缩后加入山梨酸钾,分装灭菌即得;
其中,步骤1)、2)无先后顺序。
与现有技术相比,本发明的有益效果为:
(1)药效好,纯中药配方,无明显的毒副反应;
(2)以口服液的形式用药,服用方便,效果好;
(3)能有效提升免疫力,抗疲劳和抗肿瘤作用显著。
具体实施方式
本发明涉及一种鹿胶口服液,按重量份计,主要由以下原料组份制成:
鹿胶30~90份、人参30~90份、海绵胶煤炱菌多糖10~30份以及黄精90~150份。
优选的,如上所述的鹿胶口服液,按重量份计,主要由以下原料组份制成:
鹿胶50~70份、人参50~70份、海绵胶煤炱菌多糖15~25份以及黄精110~130份。
更优选的,如上所述的鹿胶口服液,按重量份计,主要由以下原料组份制成:
鹿胶60份、人参60份、海绵胶煤炱菌多糖20份以及黄精120份。
鹿胶为鹿皮胶,优选为梅花鹿(Cervus nippon Temminck)的皮熬制的鹿皮胶。
人参(Panax ginseng C.A.Mey)为多年生草本植物,具有肉质的根,可药用。人参属于五加科,主要生长在东亚,特别是寒冷地区。人参是亚洲常见药材,用于愈后恢复、增强体力、调节荷尔蒙、降低血糖和控制血压、控制肝指数和肝功能保健等。
海绵胶煤炱菌(Scorias spongiosa)具有大型胶质、石花菜状的子实体,具有重要的食用价值。近年来的研究表明,海绵胶煤炱菌具有较强的抗肿瘤活性,但对其其他的药用价值研究较少。
黄精(Polygonatum sibiricum),又名:鸡头黄精、黄鸡菜、笔管菜、爪子参、老虎姜、鸡爪参。为黄精属植物,根茎横走,圆柱状,结节膨大。叶轮生,无柄。药用植物,具有补脾,润肺生津的作用。
本发明将既定重量份数的鹿胶、人参、海绵胶煤炱菌多糖与黄精进行配伍,制得的鹿胶口服液有效成分含量高,服用量小,可取得增强机体免疫力、抗疲劳、抗肿瘤的多重效果。
优选的,如上所述的鹿胶口服液,所述海绵胶煤炱菌多糖的制备方法包括:
将海绵胶煤炱菌子实体切片后粉碎成粉,无水乙醇浸泡脱脂后过滤得到药渣;
将所述药渣用热水浸提,将所得滤液浓缩后加无水乙醇析出沉淀,离心后将沉淀真空冷冻干燥既得。
经检测,本发明提供的海绵胶煤炱菌多糖的纯度可以达到78~80%。
优选的,如上所述的鹿胶口服液,所述无水乙醇浸泡脱脂具体为:
按照1g海绵胶煤炱菌粉:4mL~6mL无水乙醇的比例混合,浸泡8h~16h;
更优选的,所述无水乙醇浸泡脱脂具体为:
按照1g海绵胶煤炱菌粉:5mL无水乙醇的比例混合,浸泡10h~14h。
优选的,如上所述的鹿胶口服液,所述热水浸提具体为:
将所述药渣按照1g药渣:10mL~16mL水的比例浸泡12h~16h后,加热至95℃~100℃提取3h~5h;重复上述步骤2~4次;
更优选的,所述热水浸提具体为:
将所述药渣按照1g药渣:12mL~14mL水的比例浸泡13h~15h后,加热至95℃~100℃提取4h;重复上述步骤3次。
优选的,如上所述的鹿胶口服液,按重量份计,其原料组份还包括:
白砂糖100~150份、山梨酸钾0.3~0.5份;
更优选为白砂糖110~140份、山梨酸钾0.3~0.5份;或白砂糖120~130份、山梨酸钾0.4份。
本发明还涉及如上所述鹿胶口服液的制备方法,包括:
1).将人参、黄精用热水浸提后离心后收集上清,浓缩后得到药材浸提液;
2).将鹿胶、海绵胶煤炱菌多糖、白砂糖加入热水中融化并充分混匀制得胶糖液;
3).将所述药材浸提液和所述胶糖液混合,离心后收集上清,浓缩后加入山梨酸钾,分装灭菌即得;
其中,步骤1)、2)无先后顺序。
优选的,如上所述的制备方法,在步骤1)中,所述热水浸提具体包括:
按照1g药材:6mL~8mL水的比例热水提取3~4小时,过滤收集滤液;
按照1g滤渣:4mL~6mL水的比例热水提取2~3小时,过滤收集滤液;
按照1g滤渣:2mL~4mL水的比例热水提取1~2小时,过滤收集滤液;
合并三次滤液得到所述药材浸提液;
所述热水的温度为95℃~100℃。
优选的,如上所述的制备方法,在步骤2)中,所加热水的量为所述鹿胶体积的3~4倍。
优选的,如上所述的制备方法,在步骤1)中,所述浓缩具体为浓缩至20℃时的相对密度≥1.06;
优选的,在步骤3)中,所述浓缩具体为浓缩至20℃时的相对密度≥1.06。
下面将结合实施例对本发明的实施方案进行详细描述,但是本领域技术人员将会理解,下列实施例仅用于说明本发明,而不应视为限制本发明的范围。实施例中未注明具体条件者,按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者,均为可以通过市售购买获得的常规产品。
实施例1
本实施例提供了一种鹿胶口服液的制作方法,包括如下步骤:
1、将检验合格的人参40g、黄精130g进行挑选、清洗、切片备用;
2、将步骤1中清洗后的原料转入中药提取罐中,按照1g药材:6mL水的比例热水提取4小时,过滤收集滤液备用;
3、将步骤2剩余滤渣再放入提取罐,按照1g滤渣:6mL水的比例热水提取2小时,过滤收集滤液备用;
4、将步骤3剩余滤渣再放入提取罐,按照1g滤渣:2mL水的比例热水提取1小时,合并三次滤液,弃滤渣;
5、将合并的滤液经4000rpm离心10min进行分离,收集上清,弃沉淀;
6、将步骤5所得上清液进行真空浓缩直至相对密度≥1.06(20℃);
7、将海绵胶煤炱菌子实体切片后粉碎成粉按照1g海绵胶煤炱菌粉:4mL无水乙醇的比例混合,浸泡16h,过滤得到药渣;
将所述药渣按照1g药渣:10mL水的比例浸泡12h后,加热至95℃~100℃提取3h;重复上述步骤2次,将所得滤液浓缩后加无水乙醇析出沉淀,离心后将沉淀真空冷冻干燥既得海绵胶煤炱菌多糖。
8、取检验合格的鹿胶块40g打碎放入夹层锅中,加入3倍体积水,加热溶解,期间不断搅拌,待溶液形成均匀胶液后加入海绵胶煤炱菌多糖10g、白砂糖100g继续搅拌,充分混匀制成胶糖液;
9、将步骤6所得浓缩液与步骤8所得胶糖液混合,4000rpm离心10min进行分离,收集上清,弃沉淀,上清混合液经真空浓缩直至相对密度≥1.06(20℃),加入山梨酸钾0.3g,过滤;
10、将步骤9所得滤液分装,116℃灭菌30min,既得。
实施例2
本实施例提供了一种鹿胶口服液的制作方法,包括如下步骤:
1、将检验合格的人参80g、黄精70g进行挑选、清洗、切片备用;
2、将步骤1中清洗后的原料转入中药提取罐中,按照1g药材:8mL水的比例热水提取3小时,过滤收集滤液备用;
3、将步骤2剩余滤渣再放入提取罐,按照1g滤渣:4mL水的比例热水提取3小时,过滤收集滤液备用;
4、将步骤3剩余滤渣再放入提取罐,按照1g滤渣:4mL水的比例热水提取1小时,合并三次滤液,弃滤渣;
5、将合并的滤液经4000rpm离心10min进行分离,收集上清,弃沉淀;
6、将步骤5所得上清液进行真空浓缩直至相对密度≥1.06(20℃);
7、将海绵胶煤炱菌子实体切片后粉碎成粉按照1g海绵胶煤炱菌粉:6mL无水乙醇的比例混合,浸泡8h,过滤得到药渣;
将所述药渣按照1g药渣:16mL水的比例浸泡16h后,加热至95℃~100℃提取5h;重复上述步骤4次,将所得滤液浓缩后加无水乙醇析出沉淀,离心后将沉淀真空冷冻干燥既得海绵胶煤炱菌多糖。
8、取检验合格的鹿胶块80g打碎放入夹层锅中,加入4倍体积水,加热溶解,期间不断搅拌,待溶液形成均匀胶液后加入海绵胶煤炱菌多糖30g、白砂糖150g继续搅拌,充分混匀制成胶糖液;
9、将步骤6所得浓缩液与步骤8所得胶糖液混合,4000rpm离心10min进行分离,收集上清,弃沉淀,上清混合液经真空浓缩直至相对密度≥1.06(20℃),加入山梨酸钾0.5g,过滤;
10、将步骤9所得滤液分装,116℃灭菌30min,既得。
实施例3
本实施例提供了一种鹿胶口服液的制作方法,包括如下步骤:
1、将检验合格的人参60g、黄精120g进行挑选、清洗、切片备用;
2、将步骤1中清洗后的原料转入中药提取罐中,按照1g药材:7mL水的比例热水提取3小时,过滤收集滤液备用;
3、将步骤2剩余滤渣再放入提取罐,按照1g滤渣:5mL水的比例热水提取2~3小时,过滤收集滤液备用;
4、将步骤3剩余滤渣再放入提取罐,按照1g滤渣:3mL水的比例热水提取1~2小时,合并三次滤液,弃滤渣;
5、将合并的滤液经4000rpm离心10min进行分离,收集上清,弃沉淀;
6、将步骤5所得上清液进行真空浓缩直至相对密度≥1.06(20℃);
7、将海绵胶煤炱菌子实体切片后粉碎成粉按照1g海绵胶煤炱菌粉:5mL无水乙醇的比例混合,浸泡12h,过滤得到药渣;
将所述药渣按照1g药渣:13mL水的比例浸泡14h后,加热至95℃~100℃提取4h;重复上述步骤3次,将所得滤液浓缩后加无水乙醇析出沉淀,离心后将沉淀真空冷冻干燥既得海绵胶煤炱菌多糖。
8、取检验合格的鹿胶块60g打碎放入夹层锅中,加入3~4倍体积水,加热溶解,期间不断搅拌,待溶液形成均匀胶液后加入海绵胶煤炱菌多糖20g、白砂糖130g继续搅拌,充分混匀制成胶糖液;
9、将步骤6所得浓缩液与步骤8所得胶糖液混合,4000rpm离心10min进行分离,收集上清,弃沉淀,上清混合液经真空浓缩直至相对密度≥1.06(20℃),加入山梨酸钾0.4g,过滤;
10、将步骤9所得滤液分装,116℃灭菌30min,既得。
实验例1
抗疲劳活性:强迫游泳实验建立疲劳模型。操作方法为:每天10:00AM~3:00PM,将小鼠单独放入盛有23-25℃,10cm高的水的塑料圆柱体(高25cm,直径10cm)中。每只小鼠被迫在水中6min,当小鼠终止挣扎,保持漂浮的状态(或仅有微小的动作以保持头部露出水面)则被认为是固定不动。总测试时间6min,前2min为适应期,后4min记录固定不动时间。每天给药后30min进行实验,连续15天,手动双盲法记录小鼠的固定不动时间和游泳时间。每只小鼠游泳结束后更换容器中的水。实验动物分组:将雄性ICR小鼠随机分组,每组20只。分别为生理盐水组(强迫游泳同时给予生理盐水组)、给药组(强迫游泳同时给实施例1~3制备得到的鹿胶口服液)、对照组1(制备方法同实施例3,区别仅在于组分中不含海绵胶煤炱菌多糖,而替换为等质量的鹿胶)、对照组2(制备方法同实施例3,区别仅在于组分中不含鹿胶,而替换为等质量的海绵胶煤炱菌多糖)。
各组给药剂量为3ml/kg/天,每天2次,每天固定时间进行强迫游泳实验,记录小鼠固定不动时间和游泳时间。结果表明,鹿胶口服液能够显著降低疲劳小鼠的固定不动时间,效果比对照组1更为显著。且对照组2并没有产生抗疲劳的效果,因此,这说明鹿胶口服液具有显著的缓解体力疲劳的功效,且添加一定量的海绵胶煤炱菌多糖效果会更好。
表1小鼠强迫游泳实验固定不动时间统计表
实验例2
将60只18~22g昆明种雌性小白鼠随机分为6组,每组10只,分别为对照组1和2(设置方式同实验例1)、实验组1~3,生理盐水组。其中,各组给药剂量为3ml/kg/天,每天2次,连续服用30天,抽取小鼠血液,检测血清中溶血素的含量,并在抽血之后每组分别取5只进行ConA诱导的小鼠脾淋巴细胞转化实验,取5只进行小鼠迟发性变态反应实验,具体检测结果见表2。
根据表2所示数据可知,实施例1~3制备的鹿胶口服液能够显著增强小鼠的免疫力,并且通过比较对照组1~2和生理盐水组可知,若组分中缺少鹿胶或者海绵胶煤炱菌多糖也会保留一定的免疫功能的增强,但复配后的实验例中明显效果更佳。
表1鹿胶口服液对小鼠免疫功能的影响
实验例3
1、取实施例1~3和对照组1~2制备的鹿胶口服液,用DMEM培养基稀释,制成每毫升DMEM培养基含200μL所述鹿胶口服液。
2、细胞增殖的测定(MTT法):取对数生长期的Hela细胞,以1×104个/孔接种到96孔培养皿中,过夜贴皿后,分别加入200μL不含提取液的DMEM培养基(空白对照组)、含实施例1~3所述鹿胶口服液的提取液的DMEM培养基和含对照组1~2所述鹿胶口服液的DMEM培养基,培养72h后,加入5mg/mL的MTT 20μl,37℃孵育4h,弃上清,每孔空加入200μl DMSO,振荡,使结晶溶解,上机检测570nm处吸光度A值。细胞生长抑制率=(1-实验组或对比组平均A值/对照组平均A值)×100%。具体检测结果见表3。
3、流式细胞仪检测细胞凋亡率:Hela细胞按1×105个/mL接种于6孔板中,24h后分别换1mL不含提取液的DMEM培养基(空白对比组)、含实施例1~3所述鹿胶口服液的DMEM培养基和含对照组1~2所述鹿胶口服液的DMEM培养基;48h后,用胰酶消化收集各组细胞,用Annexin V-FITC Kit检测样本中凋亡细胞所占比率。具体检测结果见表3。
表3鹿胶口服液对Hela细胞增殖和凋亡的影响
细胞生长抑制率(%) | 细胞凋亡率(%) | |
空白对比组 | 0 | 2.13 |
实验组1 | 43.3 | 27.4 |
实验组2 | 48.7 | 30.3 |
实验组3 | 47.8 | 31.4 |
对照组1 | 11.3 | 5.82 |
对照组2 | 30.2 | 18.96 |
结论:鹿胶口服液能够抑制肿瘤细胞生长导致肿瘤细胞死亡,该样品具有良好的抗肿瘤效果。
最后应说明的是:以上各实施例仅用以说明本发明的技术方案,而非对其限制;尽管参照前述各实施例对本发明进行了详细的说明,但本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分或者全部技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的范围。
Claims (10)
1.一种鹿胶口服液,其特征在于,按重量份计,主要由以下原料组份制成:
鹿胶30~90份、人参30~90份、海绵胶煤炱菌多糖10~30份以及黄精90~150份。
2.根据权利要求1所述的鹿胶口服液,其特征在于,按重量份计,主要由以下原料组份制成:
鹿胶50~70份、人参50~70份、海绵胶煤炱菌多糖15~25份以及黄精110~130份。
3.根据权利要求1或2所述的鹿胶口服液,其特征在于,所述海绵胶煤炱菌多糖的制备方法包括:
将海绵胶煤炱菌子实体切片后粉碎成粉,无水乙醇浸泡脱脂后过滤得到药渣;
将所述药渣用热水浸提,将所得滤液浓缩后加无水乙醇析出沉淀,离心后将沉淀真空冷冻干燥既得。
4.根据权利要求3所述的鹿胶口服液,其特征在于,所述无水乙醇浸泡脱脂具体为:
按照1g海绵胶煤炱菌粉:4mL~6mL无水乙醇的比例混合,浸泡8h~16h。
5.根据权利要求3所述的鹿胶口服液,其特征在于,所述热水浸提具体为:
将所述药渣按照1g药渣:10mL~16mL水的比例浸泡12h~16h后,加热至95℃~100℃提取3h~5h;重复上述步骤2~4次。
6.根据权利要求1或2所述的鹿胶口服液,其特征在于,按重量份计,其原料组份还包括:
白砂糖100~150份、山梨酸钾0.3~0.5份。
7.权利要求1~6任一项所述鹿胶口服液的制备方法,其特征在于,包括:
1).将人参、黄精用热水浸提后离心后收集上清,浓缩后得到药材浸提液;
2).将鹿胶、海绵胶煤炱菌多糖、白砂糖加入热水中融化并充分混匀制得胶糖液;
3).将所述药材浸提液和所述胶糖液混合,离心后收集上清,浓缩后加入山梨酸钾,分装灭菌即得;
其中,步骤1)、2)无先后顺序。
8.根据权利要求7所述的制备方法,其特征在于,在步骤1)中,所述热水浸提具体包括:
按照1g药材:6mL~8mL水的比例热水提取3~4小时,过滤收集滤液;
按照1g滤渣:4mL~6mL水的比例热水提取2~3小时,过滤收集滤液;
按照1g滤渣:2mL~4mL水的比例热水提取1~2小时,过滤收集滤液;
合并三次滤液得到所述药材浸提液;
所述热水的温度为95℃~100℃。
9.根据权利要求7所述的制备方法,其特征在于,在步骤2)中,所加热水的量为所述鹿胶体积的3~4倍。
10.根据权利要求7所述的制备方法,其特征在于,在步骤1)中,所述浓缩具体为浓缩至20℃时的相对密度≥1.06;
优选的,在步骤3)中,所述浓缩具体为浓缩至20℃时的相对密度≥1.06。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710591759.5A CN107349332A (zh) | 2017-07-19 | 2017-07-19 | 一种鹿胶口服液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710591759.5A CN107349332A (zh) | 2017-07-19 | 2017-07-19 | 一种鹿胶口服液及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107349332A true CN107349332A (zh) | 2017-11-17 |
Family
ID=60285231
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710591759.5A Pending CN107349332A (zh) | 2017-07-19 | 2017-07-19 | 一种鹿胶口服液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107349332A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111493319A (zh) * | 2020-06-08 | 2020-08-07 | 解德俊 | 一种增强免疫功能的组合物及其制备方法 |
CN112516245A (zh) * | 2020-11-08 | 2021-03-19 | 无锡康霸水处理设备有限公司 | 一种晚期癌症患者用中药营养食品配方 |
CN114209717A (zh) * | 2021-12-29 | 2022-03-22 | 贵州广济堂健康药业有限公司 | 鹿胶及其药物组合物和用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1085785A (zh) * | 1993-05-04 | 1994-04-27 | 宝鸡民族医药保健品厂 | 参鹿益元膏及其制备方法 |
CN104940606A (zh) * | 2015-06-09 | 2015-09-30 | 贵州广济堂药业有限公司 | 调理八种偏颇体质的鹿胶保健品 |
CN106509523A (zh) * | 2016-09-30 | 2017-03-22 | 林伟欣 | 鹿胶饮料 |
-
2017
- 2017-07-19 CN CN201710591759.5A patent/CN107349332A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1085785A (zh) * | 1993-05-04 | 1994-04-27 | 宝鸡民族医药保健品厂 | 参鹿益元膏及其制备方法 |
CN104940606A (zh) * | 2015-06-09 | 2015-09-30 | 贵州广济堂药业有限公司 | 调理八种偏颇体质的鹿胶保健品 |
CN106509523A (zh) * | 2016-09-30 | 2017-03-22 | 林伟欣 | 鹿胶饮料 |
Non-Patent Citations (1)
Title |
---|
冯望等: "海绵胶煤炱菌酶活性与多糖抗氧化活性的研究", 《食品与发酵科技》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111493319A (zh) * | 2020-06-08 | 2020-08-07 | 解德俊 | 一种增强免疫功能的组合物及其制备方法 |
CN112516245A (zh) * | 2020-11-08 | 2021-03-19 | 无锡康霸水处理设备有限公司 | 一种晚期癌症患者用中药营养食品配方 |
CN114209717A (zh) * | 2021-12-29 | 2022-03-22 | 贵州广济堂健康药业有限公司 | 鹿胶及其药物组合物和用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103992924B (zh) | 增强机体免疫力的保健露酒及其制作方法 | |
CN104322617B (zh) | 一种辅助降血糖的饼干及其制备方法 | |
CN103734428B (zh) | 一种提高免疫力的女贞子保健茶及其制备方法 | |
CN102551065B (zh) | 一种降糖食品系列 | |
CN109329680A (zh) | 一种含人参提取物的组合物及由其制得的功能性饮料 | |
CN107349332A (zh) | 一种鹿胶口服液及其制备方法 | |
CN103340405B (zh) | 一种缓解体力疲劳的保健食品及其制备方法 | |
CN105395706A (zh) | 用于糖尿病的保健品 | |
CN105623995B (zh) | 山里红开胃酒及饮料及其制备方法 | |
CN107912771A (zh) | 一种具有增强免疫功能的石斛组合物及其制备方法 | |
CN107836619A (zh) | 一种具有增强免疫力和抗疲劳作用的牛大力固体饮料及其制备方法 | |
CN103583625A (zh) | 一种杜仲营养保健面包 | |
CN103404640A (zh) | 一种扶肝养胃茶及其制备方法 | |
CN104922548A (zh) | 治疗蛔虫症的中药制剂 | |
CN104187246A (zh) | 一种功能性红糖及其制备方法 | |
CN108186966A (zh) | 一种预防或改善老年痴呆症的组合物及其应用 | |
CN107737280A (zh) | 用于治疗糖尿病的中药组合物及其制备方法和应用 | |
CN103598286A (zh) | 一种绞股蓝营养保健面包 | |
CN103168870A (zh) | 一种减肥保健茶及其制备方法 | |
CN103169072A (zh) | 一种人参组合物、制备方法及其用途 | |
CN102669355B (zh) | 一种凉茶及其制备方法 | |
CN110101813A (zh) | 一种治疗肾阳虚牡蛎组合物口服液制备方法及其应用 | |
CN104256821A (zh) | 一种玛咖复方口服液及其制备方法 | |
CN103494959B (zh) | 一种治疗高血压的药物 | |
CN103583627B (zh) | 一种红景天营养保健面包 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171117 |